Numinus has received amendments to its federal licence to allow the possession, production, assembly, sale, export, and delivery of a range of psychedelics including ketamine and LSD. This development expands the work that Numinus can conduct, including the possibility of offering psychedelics testing among other services. CSO Sharan Sidhu explained: we can now develop and implement standardized…


Previous articleMINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
Next articleSilo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis